Cell Therapy Market Size & Growth Forecast 2027–2036, By Segments (Therapy Type, Therapeutic Area), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Cell Therapy Market size was more than USD 8.38 billion in 2026 and is set to grow at a 21.53% CAGR between 2027 and 2036, crossing USD 58.9 billion by 2036. The industry revenue for 2027 is assessed at USD 9.9 billion.

• Base Year Value (2026): USD 8.38 billion
• CAGR (2027-2036): 21.53%
• Forecast Year Value (2036): USD 58.9 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Cell Therapy Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads with 61.64% share, supported by advanced clinical research infrastructure, strong biotech presence, and efficient regulatory pathways enabling faster therapy development and adoption.
  • Asia Pacific is projected at 24.42% CAGR, driven by rising biopharmaceutical investment, expanding clinical development activity, improving research infrastructure, and broader adoption of advanced therapeutics.

• Segment Momentum:

  • Autologous Therapies captured an 86.66% share in 2026, supported by established clinical use, physician familiarity, and patient-specific treatment approaches that align well with existing treatment workflows and immune compatibility requirements.
  • Musculoskeletal Disorders are the fastest-growing therapeutic area as demand rises for regenerative treatments addressing chronic tissue damage, functional recovery, and conditions where conventional therapies deliver limited restorative outcomes.

• Market Expansion Drivers:

  • Rising clinical trial funding accelerating commercialization of advanced personalized cell therapies.
  • Expansion of cell manufacturing and banking infrastructure supporting large-scale therapy production.
  • Growing stem cell and iPSC research collaborations advancing regenerative treatment development pipelines.

• Leading Market Participants:

  Top companies in the cell therapy market include Novartis AG (Switzerland), Gilead Sciences, Inc. (United States), Bristol-Myers Squibb Company (United States), Johnson & Johnson (United States), Roche Holding AG (Switzerland), AstraZeneca plc (United Kingdom), Takeda Pharmaceutical Company Limited (Japan), Bluebird Bio, Inc. (United States), Legend Biotech Corporation (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 8.38 billion
  • 2027 Estimated Market Size: USD 9.9 billion.
  • Projected Market Size: USD 58.9 billion by 2036
  • Growth Forecasts: 21.53% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Autologous Therapies (Therapy Type) | Oncology (Therapeutic Area)
  • Emerging Opportunity Segment: Allogeneic Therapies (Therapy Type) | Musculoskeletal Disorders (Therapeutic Area)

Market Growth Drivers and Industry Trends

Rising clinical trial funding accelerating commercialization of advanced personalized cell therapies

Increasing investment in clinical research will propel the cell therapy market as greater funding supports the development, validation, and commercialization of personalized treatments. Cell therapies often require extensive research to establish safety, therapeutic effectiveness, manufacturing consistency, and appropriate patient selection, making sustained clinical investment essential for advancing candidates through development stages. Increased trial activity also strengthens demand for specialized research, manufacturing, analytical, and regulatory capabilities associated with the development of advanced cellular treatments.

Expansion of cell manufacturing and banking infrastructure supporting large-scale therapy production

The cell therapy market growth is supported by expansion of manufacturing and cell banking infrastructure, which is essential for producing, storing, processing, and distributing cellular materials under controlled conditions. Advanced therapies require specialized facilities capable of maintaining cell quality and viability throughout collection, processing, expansion, preservation, and delivery. Greater availability of manufacturing capacity and banking systems can improve production scalability while supporting standardized workflows and the logistical requirements associated with patient-specific and broader cell therapy programs.

Growing stem cell and iPSC research collaborations advancing regenerative treatment development pipelines

Growing collaboration around stem cell and induced pluripotent stem cell research is expanding the cell therapy market by supporting discovery of new approaches to tissue repair and regenerative medicine. iPSC technologies can provide researchers with adaptable cellular platforms for studying disease mechanisms, evaluating therapeutic candidates, and developing differentiated cell populations for potential treatment applications. Collaborative research programs bring together expertise in cell biology, disease modeling, manufacturing, and translational medicine, helping advance experimental therapies through increasingly sophisticated development pathways.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising clinical trial funding accelerating commercialization of advanced personalized cell therapies	2.60%	High	North America, Europe	High	Near Term
Expansion of cell manufacturing and banking infrastructure supporting large-scale therapy production	2.20%	High	North America, Asia Pacific	High	Mid Term
Growing stem cell and iPSC research collaborations advancing regenerative treatment development pipelines	1.90%	High	Europe, Asia Pacific	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America led the cell therapy market with a 61.64% share in 2026, underpinned by advanced biomedical research capabilities, strong clinical development infrastructure, and a well-developed ecosystem for innovative therapies. The region benefits from extensive investment in regenerative medicine and advanced therapeutic platforms, alongside established capabilities in cell processing, manufacturing, clinical research, and specialized healthcare delivery. Increasing interest in personalized treatment approaches is also supporting the development and adoption of cell-based therapies for complex diseases. In addition, a sophisticated regulatory and healthcare environment, combined with strong collaboration among research institutions, healthcare organizations, and biotechnology developers, facilitates the translation of cell therapy innovations from research into clinical applications.

Asia Pacific is expected to experience the fastest market development as healthcare systems increasingly invest in advanced therapeutic technologies and biotechnology infrastructure. Rising demand for innovative treatments, expanding clinical research capabilities, and growing investments in regenerative medicine are strengthening the regional cell therapy ecosystem. Improvements in specialized manufacturing and treatment infrastructure are also helping address the technical requirements associated with cell-based therapies. Furthermore, increasing healthcare awareness and the expansion of advanced medical services are creating broader opportunities for adoption, while supportive initiatives aimed at strengthening biotechnology research and domestic healthcare capabilities are encouraging continued investment in cell therapy development.

Key Country Insights

United States

Clinical Development Ecosystem

The U.S. cell therapy market benefits from strong collaboration among biotechnology companies, research institutions, and specialized treatment centers. Organizations across the U.S. prioritize manufacturing scalability, clinical validation, and efficient delivery models for advanced therapeutic applications.

Japan

Regenerative Medicine Innovation

Japan advances the cell therapy market by supporting regenerative medicine research and streamlined clinical development pathways. Japanese companies emphasize manufacturing consistency and translational research that facilitates broader adoption of advanced therapeutic technologies.

South Korea

Bioprocess Expansion Strategy

South Korea continues expanding cell therapy capabilities through investments in bioprocess technologies, contract manufacturing, and clinical development infrastructure. South Korean organizations strengthen collaboration between biotechnology developers and healthcare providers to improve commercialization readiness.

Germany

Advanced Manufacturing Standards

Germany focuses on strengthening cell therapy manufacturing capabilities through high-quality production processes and rigorous quality management. German stakeholders continue investing in specialized facilities that support consistent product development and clinical application.

France

Translational Research Networks

France supports the cell therapy market through coordinated research collaborations linking academic institutions, hospitals, and biotechnology companies. French stakeholders prioritize standardized manufacturing practices and clinical evidence generation to strengthen therapeutic adoption.

Italy

Specialized Clinical Adoption

Italy emphasizes the integration of cell therapy into specialized treatment centers supported by academic research and clinical expertise. Italian healthcare institutions continue strengthening manufacturing partnerships and treatment capabilities for advanced therapeutic applications.

Segment Leadership and Growth Trends

 

Therapy Type Segment Analysis: Autologous Therapies (Largest Segment) vs Allogeneic Therapies (Fastest-Growing Segment)

Autologous therapies accounted for an 86.66% share of the cell therapy market in 2026, reflecting their established position in clinical development and therapeutic adoption. These therapies use a patient's own cells, which can provide important advantages related to biological compatibility and reduced concerns associated with immune rejection. Continued advances in cell collection, processing, expansion, and administration are supporting the development of autologous approaches across major therapeutic applications. Their strong clinical presence and growing integration with personalized medicine strategies further reinforce their leading position, particularly where treatment approaches are designed around patient-specific biological characteristics.

Allogeneic therapies represent the fastest-growing segment as the cell therapy industry increasingly focuses on scalable and potentially more accessible treatment models. The use of donor-derived cells can support the development of standardized therapeutic products and may improve manufacturing efficiency compared with approaches requiring individualized cell collection for every patient. Progress in cell engineering, donor-cell selection, immune compatibility strategies, and manufacturing technologies is strengthening the commercial potential of allogeneic approaches. These developments are also encouraging broader interest in cell therapies that can be produced and distributed using more standardized processes.

Therapeutic Area Segment Analysis: Oncology (Largest Segment) vs Musculoskeletal Disorders (Fastest-Growing Segment)

The oncology segment held the largest share of the cell therapy market in 2026, supported by the substantial unmet need for innovative treatments for complex and difficult-to-treat cancers. Cell-based approaches have gained strong attention in oncology because they can be designed to harness or modify immune and cellular mechanisms to target malignant cells. Continued research into personalized therapies, immune-cell engineering, and treatment strategies for hematological and solid tumors is sustaining investment and clinical activity in this area. The growing focus on precision medicine and therapies capable of addressing treatment resistance further supports oncology's leading position within the market.

Musculoskeletal disorders are the fastest-growing therapeutic area as cell-based approaches attract increasing attention for tissue repair, regeneration, and restoration of impaired function. Rising interest in regenerative medicine is encouraging the investigation of cell therapies for conditions affecting bones, cartilage, muscles, and connective tissues. Advances in cell sourcing, tissue engineering, biomaterials, and regenerative treatment strategies are improving the potential for targeted interventions that address underlying tissue damage rather than focusing solely on symptom management. This expanding therapeutic focus is strengthening the role of cell therapy in musculoskeletal care and broadening its applications beyond oncology.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Therapy Type	Allogeneic Therapies, Autologous Therapies	Autologous Therapies	Allogeneic Therapies
Therapeutic Area	Oncology, Cardiovascular Disease (CVD), Musculoskeletal Disorders, Dermatology, Others	Oncology	Musculoskeletal Disorders

Competitive Landscape and Market Positioning

Leading companies in the cell therapy market:

1. Novartis AG (Switzerland)

2. Gilead Sciences Inc. (United States)

3. Bristol-Myers Squibb Company (United States)

4. Johnson & Johnson (United States)

5. Roche Holding AG (Switzerland)

6. AstraZeneca plc (United Kingdom)

7. Takeda Pharmaceutical Company Limited (Japan)

8. Bluebird Bio Inc. (United States)

9. Legend Biotech Corporation (United States)

The cell therapy sector is advancing through strong scientific innovation and clinical progress. In the cell therapy market, research-driven development is enabling breakthrough treatment approaches. New therapy introductions are expanding clinical possibilities, while collaborative research ecosystems are accelerating innovation cycles.

Industry Development/News

Company Name	Date	Key Development
Gilead Sciences	Feb-26	Gilead Sciences acquired Arcellx in a $7.8 billion transaction, significantly bolstering its CAR-T cell therapy portfolio. The deal integrates high-value late-stage assets into Gilead’s pipeline, reinforcing its competitive leadership in the cell therapy market and accelerating its strategy to capture a larger share of advanced oncology treatment markets.
UCLA Health	May-26	UCLA opened the 14,000-square-foot Center for Advanced Biotherapies, an FDA-compliant manufacturing facility. The site effectively doubles the institution's capacity to produce cell and gene therapies for clinical trials, strengthening its institutional-scale infrastructure and operational ability to support a growing portfolio of advanced therapeutic research and patient-focused applications.
UCB	Apr-26	UCB completed the acquisition of Neurona for over $650 million, marking a major strategic expansion into regenerative medicine. By integrating advanced cell therapy modalities, the move strengthens UCB's neurology pipeline and diversifies its portfolio, positioning the company to address significant unmet needs in complex neurodegenerative conditions through advanced biological therapies.
AstraZeneca	Mar-26	AstraZeneca announced plans to construct an integrated cell therapy manufacturing hub and R&D center in Shanghai. This initiative establishes end-to-end development and production capabilities within the Chinese market, facilitating the company’s strategic expansion into Asia and enhancing its localized supply chain for advanced cellular therapeutics.
Johnson & Johnson	Feb-26	Johnson & Johnson committed over $1 billion to construct a new cell therapy manufacturing facility in the U.S. This substantial investment aims to significantly increase internal production capacity, providing the necessary scale to support the manufacturing demands of its expanding pipeline of advanced therapeutic assets.
Cellply	May-26	Cellply secured €7.15 million in new funding to accelerate the global commercialization of its cell therapy analytical platform. The capital supports the rollout of the VivaCyte system, designed for high-precision single-cell characterization, which addresses critical quality control and development bottlenecks for immunotherapies and other advanced cell-based therapies.
Vertex Pharmaceuticals	Jun-23	Vertex Pharmaceuticals and Lonza formed a joint venture to manufacture Vertex’s portfolio of investigational stem cell therapies. The partnership focuses on scaling the production of VX-880 and VX-264 programs, which are currently undergoing clinical trials as part of a therapeutic effort to treat Type 1 Diabetes through advanced regenerative cell technologies.
Johnson & Johnson	May-23	Johnson & Johnson entered a global collaboration and licensing agreement with Cellular Biomedicine Group to develop next-generation CAR-T cell therapies. This partnership leverages joint expertise to accelerate the development of innovative oncology treatments, strengthening J&J’s long-term research pipeline for highly specialized, engineered cell-based cancer immunotherapies.
Bristol-Myers Squibb	May-23	The European Commission granted approval for Breyanzi for the treatment of adult patients with refractory or relapsed large B-cell lymphoma. This regulatory milestone enhances the company's competitive position in the European oncology market, expanding access to its CAR-T therapy for patients who have exhausted traditional treatment options.
Nkarta, Inc.	Oct-23	The FDA approved the Investigational New Drug (IND) application for NKX019, an allogeneic, CD19-directed CAR NK cell therapy candidate. This clinical milestone allows Nkarta to initiate trials evaluating the candidate as a treatment for lupus nephritis, marking a strategic move to investigate the utility of off-the-shelf CAR-NK therapies in autoimmune diseases.